Aktiia was established in 2018 with the ambition to develop a solution for the diagnosis and treatment of hypertension. The founders, Mattia Bertschi (CEO) and Josep Solà (CTO) developed a cuffless blood pressure monitoring device using standard optical sensors to take accurate blood pressure readings around the clock without interrupting daily life.
The bracelet and algorithms were validated in clinical trials against arterial lines and in ambulatory settings with the University of Lausanne Hospitals. Never before has it been possible to measure blood pressure profiles around the clock over long periods of time. This valuable and unique dataset will allow for broader insights into the diagnosis and treatment of hypertension, the largest epidemic of humankind.
Adding to the CHF 4 million raised in seed funding, Aktiia has obtained CHF 6 million in new funding, led by Redalpine. The round includes a strategically recruited international investor syndicate: Translink Capital (Palo Alto), investiere (Zurich), Libra (New York), Christian Wenger (Zurich), Sparks Street Capital (Boston) and Barbaric Holdings (Montreal, Canada) underpinning the company with a global network and commercialization experience. While the company awaits the FDA clearance and CE mark, the team is will use the funds to complete the final steps of taking the solution to the market.
"Getting blood pressure data 24/7, day and night, is a paradigm shift in the daily management of hypertension and will trigger a whole range of novel health- and wellness-related applications,” stated Michael Sidler, Co-Founder and Partner of Redalpine.